# Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

> **NCT01651039** · PHASE2 · COMPLETED · sponsor: **Ajai Chari** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Panobinostat
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01651039
- **Lead sponsor:** Ajai Chari
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-12-21
- **Final completion:** 2016-12-21
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01651039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01651039, "Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT01651039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*